Disclaimer: This content is for educational purposes only and is not a substitute for medical advice. This is an FDA-approved prescription medication. Consult your healthcare provider before starting, stopping, or changing any treatment.
What Tesamorelin Is and What It's Approved For
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) that signals the pituitary to release growth hormone in physiologic pulses.
It is FDA-approved specifically to reduce excess abdominal fat in adults with HIV-associated lipodystrophy (Egrifta, FDA-approved 2010). It is not approved for general weight loss, body recomposition, or fat reduction in the broader population. Use outside this indication is off-label and should be considered investigational.
Meet the Molecule
Tesamorelin is a synthetic, 44–amino acid analog of human GHRH (GHRH 1–44). It sits in the family of growth hormone secretagogues, which prompt your pituitary to release growth hormone rather than replacing it.
Chemists added a small N-terminal trans-3-hexenoic acid group to resist rapid breakdown, extending its functional life compared with native GHRH. It is fully synthetic, so structure and purity are controlled lot to lot.
Tesamorelin is FDA-approved as a prescription injection to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Use outside that indication is off-label and should be considered investigational.
From Receptor to Results
Think of tesamorelin as a key for the GHRH receptor on pituitary somatotrophs. Turn the key, cyclic AMP signaling rises, calcium flows, and growth hormone is released in pulses that resemble physiology.
Downstream, growth hormone signals fat cells to increase lipolysis, with a particular impact on visceral depots. The liver produces insulin-like growth factor 1 (IGF‑1), which carries many of growth hormone’s effects on protein synthesis and tissue remodeling.
In trials among adults with HIV-associated lipodystrophy, visceral fat dropped by about 10 to 20 percent over roughly six months, measured by CT. Pivotal Phase 3 data show a treatment effect near 15 percent at 26 weeks, with modest triglyceride improvements. Visceral fat tends to return after discontinuation.
Using It in Practice
The validated route is subcutaneous injection. Oral forms are degraded in the gut. Nasal versions are not approved. Because tesamorelin triggers your own growth hormone pulses, circadian timing sounds appealing, but labeled use does not require a specific dosing time.
Formulation update: in 2025, the FDA cleared an F8 formulation called EGRIFTA WR that allows weekly reconstitution convenience while keeping the same active peptide. The approved dosing for the labeled indication is 1.28 mg subcutaneously once daily (EGRIFTA WR).
FDA-approved use (HIV-associated lipodystrophy)
Dose in pivotal trials (original Egrifta formulation): 2 mg subcutaneously once daily for 26 weeks, with some longer extensions. Visceral fat often rebounds after discontinuation. In practice, consistency matters more than clock time.
Research in HIV with fatty liver disease
Dose in studies: 2 mg subcutaneously once daily for 6 to 12 months. Trials have reported signals of reduced liver fat and less fibrosis progression in this group. Outside the labeled use, this remains investigational.
Off-label in the general population
No established dose, frequency, or duration for off-label use. Evidence is insufficient for routine use outside HIV-associated lipodystrophy. If considered, safety monitoring becomes essential because risks shift with baseline glucose, age, and pituitary integrity.
Safety First
Side effects fall into two buckets: local injection reactions and systemic effects of higher growth hormone and IGF‑1. Common complaints include redness or itching at the site, joint stiffness, hand swelling, tingling that can feel like carpal tunnel, headache, and nausea. These reflect fluid shifts and connective tissue changes seen with growth hormone stimulation.
Glucose deserves special attention. Growth hormone can antagonize insulin action in liver and muscle, nudging fasting glucose and A1c upward. In pivotal studies, the odds of developing diabetes were about 3.3 times higher than placebo, roughly 5 percent vs 1 percent over 26 weeks. Risks rise if you already have prediabetes or metabolic syndrome, which is why clinicians track glucose metrics when the axis is being pushed.
Hypersensitivity reactions can occur, from hives to rare systemic responses. IGF‑1 rises are expected; if levels climb above age- and sex-adjusted norms over time, the risk-benefit balance needs review. Effectiveness also depends on an intact hypothalamic-pituitary axis. If you have had pituitary surgery, radiation, or a receptor defect, the signal may be muted.
Long-term safety data are strongest out to 6 to 12 months in adults with HIV, including extension studies. The FDA label notes that long-term cardiovascular outcomes are not established, and visceral fat tends to return after stopping. Clinicians weigh this reversible benefit against risks that may accumulate with longer exposure.
Contraindications
- Pregnancy
- Known hypersensitivity to tesamorelin or its components
- Active malignancy
If a history of cancer is remote, decisions are individualized because growth hormone and IGF‑1 pathways promote cell growth. These factors should be reviewed with a clinician before starting therapy.
How It Stacks Up
Think of the growth hormone axis like a soundboard with two main knobs. One is the GHRH receptor, where tesamorelin acts. The other is the ghrelin receptor, targeted by GHRPs like ipamorelin. Both can raise growth hormone, but through different inputs.
Tesamorelin is a stabilized, full-length GHRH analog with clinical trial evidence and an FDA label in a specific population. Sermorelin is a shorter GHRH fragment. CJC‑1295 is a modified fragment designed to last longer. Those chemistry choices change pharmacokinetics and, in practice, how predictable the response is.
Compared with injecting recombinant growth hormone, secretagogues aim for a pulse that mirrors physiology. In theory, that can shift side effects and tissue specificity. Some clinics pair GHRH analogs with ghrelin mimetics to amplify pulses through dual pathways. Mechanistically, synergy is plausible, but data on combinations are thin and safety margins can narrow as IGF‑1 drifts upward. Selection depends on the clinical context and the specific patient population being treated.
Legal and Regulatory Snapshot
Tesamorelin is a prescription-only injectable approved to reduce visceral fat in adults with HIV-associated lipodystrophy. Off-label use should be framed as investigational and anchored to a clear rationale with monitoring.
Compounding rules matter. In the United States, pharmacies generally cannot compound copies of FDA-approved drugs unless specific criteria are met, such as an official shortage. Peptide products from unregulated sources can be misbranded or impure, which changes potency and safety.
For athletes, the World Anti-Doping Agency prohibits growth hormone and agents that stimulate its release. Tesamorelin is listed under S2.2.4 growth hormone releasing factors and is prohibited at all times. Chain of custody and quality must be verifiable.
Summary
Tesamorelin is a GHRH analog FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy (Egrifta, FDA-approved 2010). It triggers physiologic growth hormone release and preferentially reduces visceral adipose tissue, with benefits that wane after stopping. Side effects align with growth hormone biology, and glucose monitoring is important. Evidence outside HIV-related indications is still developing, so use in the general population should be considered investigational. Patients considering this medication should discuss appropriateness, contraindications, and monitoring with a licensed clinician.
Regulatory and Availability Status
- Regulatory Status: FDA-approved for HIV-associated lipodystrophy (Egrifta, FDA-approved 2010)
- Research Stage: Approved and marketed for specific indication
- Availability: Prescription only; off-label use requires clinician oversight
Disclaimer: This content is for educational purposes only and is not a substitute for medical advice. This is an FDA-approved prescription medication. Consult your healthcare provider before starting, stopping, or changing any treatment.
.svg)
.avif)